Frederic Jacquot

Lyon, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Hemostasis defects underlying the hemorrhagic syndrome caused by mammarenaviruses in a cynomolgus macaque model.

Hemostasis defects underlying the hemorrhagic syndrome caused by mammarenaviruses in a cynomolgus macaque model.

Journal: Blood
Published: March 06, 2023

Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques.

Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques.

Journal: Communications biology
Published: May 19, 2020

Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.

Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.

Journal: Antiviral research
Published: December 21, 2019

The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections.

The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections.

Journal: Viruses
Published: July 23, 2018

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Journal: Nature communications
Published: March 20, 2018

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Journal: Antimicrobial agents and chemotherapy
Published: December 23, 2017

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Journal: PLoS medicine
Published: August 22, 2017

Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.

Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.

Journal: Scientific reports
Published: January 22, 2017

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Journal: PLoS neglected tropical diseases
Published: September 26, 2016

Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations.

Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations.

Journal: Antiviral research
Published: September 26, 2016

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Journal: Antimicrobial agents and chemotherapy
Published: June 19, 2016

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.

Journal: PloS one
Published: February 10, 2016
Showing 1-12 of 14

Last Updated: 09/26/2026